Company Encyclopedia
View More
name
INNOVITA
688253.SH
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.
337.57 B
688253.SHMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking25/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.55%C
    • Profit Margin30.96%A
    • Gross Margin72.96%A
  • Growth ScoreE
    • Revenue YoY-40.18%E
    • Net Profit YoY-59.81%D
    • Total Assets YoY-0.63%D
    • Net Assets YoY-0.56%D
  • Cash ScoreD
    • Cash Flow Margin322.96%C
    • OCF YoY-40.18%E
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreA
    • Gearing Ratio5.76%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    INNOVITA released its performance for the first three quarters, with a net profit attributable to the parent company of 131 million yuan, a year-on-year decrease of 46.37%

    According to the Zhitong Finance APP, INNOVITA disclosed its third-quarter report for 2025. The company's revenue for the first three quarters reached 330 million yuan, a year-on-year decrease of 36.56%; the net profit attributable to the parent company was 131 million yuan, a year-on-year decrease of 46.37%; the net profit excluding non-recurring gains and losses was 112 million yuan, a year-on-year decrease of 49.96%; the basic earnings per share were 0.96 yuan

    Zhitong·
    SH
    688253
    -0.80%
    Zhitong·
    SH
    688253
    -0.80%

    INNOVITA: Net profit in the first half of the year was 125 million yuan, a year-on-year decrease of 39.36%

    INNOVITA achieved operating revenue of 276 million yuan in the first half of 2025, a year-on-year decrease of 34.35%; net profit was 125 million yuan, a year-on-year decrease of 39.36%. The company faces challenges from a decline in hospital visits and intensified industry competition. Additionally, due to policy adjustments, the value-added tax rate for some products increased from 3% to 13%, resulting in a simultaneous decline in operating revenue and profit indicators

    Zhitong·
    SH
    688253
    -0.80%
    Zhitong·
    SH
    688253
    -0.80%

    INNOVITA establishes a new health technology company

    According to the Qichacha APP, recently, Hangzhou INNOVITA Health Technology Co., Ltd. was established, with Zhang Le as the legal representative. The business scope includes: sales of Class I medical devices; sales of Class II medical devices; research and development of bio-based material technology, etc. Qichacha's equity penetration shows that the company is wholly owned by INNOVITA

    Zhitong·
    SH
    688253
    -0.80%
    Zhitong·
    SH
    688253
    -0.80%

    INNOVITA's subsidiary recently obtained a qualification

    According to the Zhitong Finance APP, INNOVITA announced that its wholly-owned subsidiary INNOVITA (Tangshan) Biotechnology Co., Ltd. (referred to as "Tangshan INNOVITA") has recently obtained a new product qualification, with the product name: Norovirus GI/GII Nucleic Acid Detection Kit (PCR Fluorescent Probe Method). The acquisition of this qualification broadens the variety of the company's products and further enhances the company's market expansion capabilities and core competitiveness

    Zhitong·
    SH
    688253
    -0.80%
    Zhitong·
    SH
    688253
    -0.80%

    INNOVITA obtained qualification for 1 product

    INNOVITA recently announced that the company has obtained a new product qualification for the Respiratory Syncytial Virus, Adenovirus, Human Metapneumovirus, and Parainfluenza Virus Antigen Combined Detection Kit (Latex Chromatography Method). This product is used for the qualitative detection of multiple viral antigens in oropharyngeal swab samples, and the acquisition of this qualification will broaden the company's product line, enhance market expansion capabilities, and strengthen core competitiveness

    Zhitong·
    SH
    688253
    -0.80%
    Zhitong·
    SH
    688253
    -0.80%
    © 2025 Longbridge｜Disclaimer